EFFICACY OF LEVETIRACETAM VERSUS PHENYTOIN AS A SECOND-LINE ANTIEPILEPTIC DRUG IN THE MANAGEMENT OF BENZODIAZEPINE-REFRACTORY STATUS EPILEPTICUS AMONG CHILDREN
Keywords:Levetiracetam, phenytoin, Antiepileptic drug, Status Epilepticus
AbstractBackground: Status Epilepticus (SE) is a life-threatening neurological emergency requiring appropriate therapy to terminate seizure activity. SE is managed with supportive measures and ultra-short-acting benzodiazepines. However, limited data is available in the paediatric population regarding the next best option when this fails. This study aimed at finding new data to recommend levetiracetam or phenytoin as the second-line option. Methods: One hundred and thirty-seven patients with status epilepticus were randomized into two groups; group-I was given IV Levetiracetam (LEV) at 20 mg/kg/dose over 5 minutes followed by a maintenance dose of 20mg/kg/dose BID, whereas Group II received phenytoin at 20mg/kg IV loading dose followed by a maintenance dose of 5–8 mg/kg/day divided BID. The primary outcome was seizure cessation, defined as the termination of the apparent convulsion 30 min after the administration of phenytoin or levetiracetam. Secondary outcomes were the use of different anti-convulsants for continued management, admittance to critical treatment, and severe adverse events (including mortality, Stevens-Johnson syndrome, rash, airway problems, cardiovascular instability, extravasation, and severe agitation). Data was recorded via a clinical proforma and was analyzed by SPSS software version 25. All numerical data were expressed in mean±SD forms, and frequency was determined for qualitative baseline data. Secondary outcomes were tested through the χ2 test, A p-value of ≤0.05 was considered statistical significance. Results: Levetiracetam terminated seizures in 94% of children compared to 77% in those treated with phenytoin. The mean time to seizure termination was 19.94±3.76 minutes for the LEV Group as compared to 23.791±9.1 min for the PHT group. (p=0.046). Regarding safety, a profile study shows LEV has fewer and less severe side effects compared to Phenytoin. Conclusion: Levetiracetam is a safe, well-tolerated, and effective treatment as a second-line antiepileptic drug in the management of status epilepticus.
Bassin S, Smith TL, Bleck TP. Clinical review: Status epilepticus. Crit Care 2002;6(2):137–42.
Trinka E, Cock H, Hesdorffer D, Rossetti AO, Scheffer IE, Shinnar S, et al. A definition and classification of status epilepticus – Report of the ILAE Task Force on Classification of Status Epilepticus. Epilepsia 2015;56(10):1515–23.
Madžar D, Geyer A, Knappe RU, Gollwitzer S, Kuramatsu JB, Gerner ST, et al. Association of seizure duration and outcome in refractory status epilepticus. J Neurol 2016;263(3):485–91.
Samuels M, Wieteska S, editors. Advanced paediatric life support: a practical approach. Sixth edition. Chichester, West Sussex, UK; Hoboken, NJ, USA: John Wiley & Sons, Ltd; 2016.
Brigo F, Bragazzi N, Nardone R, Trinka E. Direct and indirect comparison meta-analysis of levetiracetam versus phenytoin or valproate for convulsive status epilepticus. Epilepsy Behav 2016;64(Pt A):110–5.
Kapur J, Elm J, Chamberlain JM, Barsan W, Cloyd J, Lowenstein D, et al. Randomized Trial of Three Anticonvulsant Medications for Status Epilepticus. N Engl J Med 2019;381(22):2103–13.
Appleton RE, Gill A. Adverse events associated with intravenous phenytoin in children: a prospective study. Seizure 2003;12(6):369–72.
Besli GE, Yuksel Karatoprak E, Yilmaz S. Efficacy and safety profile of intravenous levetiracetam versus phenytoin in convulsive status epilepticus and acute repetitive seizures in children. Epilepsy Behav 2020;111:107289.
Wani G, Imran A, Dhawan N, Gupta A, Giri JI. Levetiracetam versus phenytoin in children with status epilepticus. J Family Med Prim Care 2019;8(10):3367–71.
Noureen N, Khan S, Khursheed A, Iqbal I, Maryam M, Sharib SM, et al. Clinical Efficacy and Safety of Injectable Levetiracetam Versus Phenytoin as Second-Line Therapy in the Management of Generalized Convulsive Status Epilepticus in Children: An Open-Label Randomized Controlled Trial. J Clin Neurol 2019;15(4):468–72.
Fiani B, Andraos C, Mabry I, Siddiqi J. A Comparison of Seizure Prophylaxis: Phenytoin Versus Levetiracetam. Cureus 2021;13(5):e14956.
Lyttle MD, Rainford NEA, Gamble C, Messahel S, Humphreys A, Hickey H, et al. Levetiracetam versus phenytoin for second-line treatment of paediatric convulsive status epilepticus (EcLiPSE): a multicentre, open-label, randomised trial. Lancet 2019;393(10186):2125–34.
DeMott JM, Slocum GW, Gottlieb M, Peksa GD. Levetiracetam vs. phenytoin as 2nd-line treatment for status epilepticus: A systematic review and meta-analysis. Epilepsy Behav 2020;111:107286.
Li L, Zhang Y, Jia L, Jia D, Faramand A, Chong W, et al. Levetiracetam versus phenytoin for the treatment of established status epilepticus: A systematic review and meta-analysis of randomized controlled trials. Seizure 2020;78:43–8.
Dalrymple RA. Phenytoin and levetiracetam are equally effective second-line treatments for status epilepticus. Arch Dis Child Educ Pract Ed 2020;105(5):319–20.
Copyright (c) 2023 Babar Naeem, Mommna Ashfaq , Mamoon Akbar Qureshi
This work is licensed under a Creative Commons Attribution-NoDerivatives 4.0 International License.
Journal of Ayub Medical College, Abbottabad is an OPEN ACCESS JOURNAL which means that all content is FREELY available without charge to all users whether registered with the journal or not. The work published by J Ayub Med Coll Abbottabad is licensed and distributed under the creative commons License CC BY ND Attribution-NoDerivs. Material printed in this journal is OPEN to access, and are FREE for use in academic and research work with proper citation. J Ayub Med Coll Abbottabad accepts only original material for publication with the understanding that except for abstracts, no part of the data has been published or will be submitted for publication elsewhere before appearing in J Ayub Med Coll Abbottabad. The Editorial Board of J Ayub Med Coll Abbottabad makes every effort to ensure the accuracy and authenticity of material printed in J Ayub Med Coll Abbottabad. However, conclusions and statements expressed are views of the authors and do not reflect the opinion/policy of J Ayub Med Coll Abbottabad or the Editorial Board.
USERS are allowed to read, download, copy, distribute, print, search, or link to the full texts of the articles, or use them for any other lawful purpose, without asking prior permission from the publisher or the author. This is in accordance with the BOAI definition of open access.
AUTHORS retain the rights of free downloading/unlimited e-print of full text and sharing/disseminating the article without any restriction, by any means including twitter, scholarly collaboration networks such as ResearchGate, Academia.eu, and social media sites such as Twitter, LinkedIn, Google Scholar and any other professional or academic networking site.